SINGAPORE, March 16, 2026 /PRNewswire/ — As 51Talk celebrates its 15th anniversary, the global one-on-one online English learning platform is entering a new stage of international growth with the launch of a comprehensive brand refresh.

For learners and parents, the upgrade introduces a clearer and more intuitive visual identity, along with warmer, more engaging product interfaces designed to encourage active participation. Simplified layouts and IP-guided interactions across lessons aim to create a more supportive, interactive, and personalized learning experience for children.

Since launching its global expansion strategy in 2021, 51Talk has expanded across key markets in Southeast Asia, the Middle East, and East Asia. The 15-year milestone represents not only sustained growth but an important step toward building a more unified and internationally recognizable education brand.

A Stronger Global Brand System

The refreshed global visual identity system is designed to deliver greater clarity, consistency, and cohesion across the company’s brand identity. The upgrade aligns brand visuals, product interfaces, and communication touchpoints, creating a seamless and intuitive experience for families worldwide.

This transition reflects 51Talk’s shift from rapid international expansion toward long-term brand building. By strengthening recognition and consistency, the company aims to deepen trust with families while supporting the next stage of its global growth.

Introducing Toki: A Learning Companion for a New Chapter

At the heart of the refresh is Toki, 51Talk’s new brand character and learning companion. More than a visual mascot, Toki embodies curiosity, confidence, and the courage to communicate.

Integrated across product interfaces, online classrooms, and brand touchpoints, Toki helps create a warmer and more engaging learning environment for young learners. By guiding children through lessons and encouraging participation, Toki reinforces a sense of companionship throughout their English learning journey.

The introduction of Toki reflects 51Talk’s belief that effective one-on-one online English education combines a structured curriculum with emotional connection, enabling children not only to learn English but also to use it confidently in real-world communication.

Reinforcing Human Interaction in the AI Era

As artificial intelligence continues to reshape how people access language and information, automated tools and translation technologies are becoming more widespread. In this context, the value of authentic human interaction in education becomes even more important.

For children, learning English today is no longer about vocabulary acquisition or exam preparation. It is about developing the confidence to speak up, express ideas clearly, and engage meaningfully with the world.

Through its one-on-one live online learning model, 51Talk ensures real-time interaction between teachers and students, emphasizing personalized guidance, immediate feedback, and meaningful communication as essential elements of effective language learning.

Looking Ahead

Fifteen years after its founding, 51Talk continues to pursue its mission: Empower Everyone to Speak Up, Stand Out and Succeed. With a stronger global brand system and an enhanced learning experience, 51Talk is preparing for its next stage of international growth, empowering more young learners to communicate confidently in an increasingly connected world.

To learn more, please visit: www.51talk.com

LONDON, March 16, 2026 /PRNewswire/ — The Unlock Her Future Prize, the annual start-up competition for female social impact entrepreneurs powered by The Bicester Collection, will debut in East and Southeast Asia in 2026 – advancing its global commitment to women-led impact and purpose-driven entrepreneurship.

Each year, guided by the philosophy of “Global Vision, Local Engagement”, the initiative travels to a new region to identify and support women launching and scaling system-changing start-ups. Following three successful regional editions: MENA (2023), LATAM (2024), and South Asia (2025), the 2026 edition welcomes applications from women aged 18 and over across East and Southeast Asia.

Applicants must present innovative ventures aligned with the United Nations Sustainable Development Goals, addressing social, cultural or environmental challenges. Start-ups may be at the idea or validation stage – with a prototype in development – or at the launch/growth stage, operating for fewer than three years and generating under US$1 million in revenue.

Transformational Support for Visionary Founders

Endorsed by UN Women and presented in partnership with Ashoka, the Unlock Her Future Prize provides a powerful global platform that unlocks potential through capital, mentorship and global visibility. By combining financial support with education and international networks, the Prize equips women entrepreneurs to build resilient businesses that deliver measurable, sustainable impact.

Each winner receives:

• A business grant of up to US$100,000
• An executive education programme delivered by leading academic partners
• Access to expert international mentors and The Bicester Collection’s global network for visibility and collaboration

Addressing the Global Funding Gap

According to Harvard Business School, fewer than 3% of women-led businesses receive venture capital funding – leaving countless high-potential ideas underfunded and underrepresented.

Launched in 2022, the Unlock Her Future Prize was created to help shift this reality. Research from The Boston Consulting Group shows that equal participation in entrepreneurship could increase global GDP by 3% to 6% – up to US$5 trillion – underscoring the economic and social imperative of investing in women founders.

Part of The Bicester Collection’s philanthropic programme DO GOOD, the Prize directly addresses structural funding gaps while strengthening a global ecosystem of women changemakers. To date, approximately US$900,000 in grants has been committed, supporting 14 ventures aligned with the UN Sustainable Development Goals.

Chantal Khoueiry, Chief Culture Officer, The Bicester Collection, said:

“Entrepreneurship can be a powerful force for systemic change. Across East and Southeast Asia, many women are building practical solutions to challenges in their communities. Through the Unlock Her Future Prize, we are proud to bring The Bicester Collection’s global platform to the region—supporting women whose ideas combine innovation with real impact and helping them access the capital, mentorship, and visibility they need to grow.”

A Growing Global Alumnae Network

The 2026 winners will join a distinguished international alumnae community of social impact leaders advancing health and well-being, quality education, climate and water resilience, and gender equality.

2023 MENA Edition winners:
Noor Jaber (Lebanon, NAWAT Health), Sara Lalla (Iraq/UAE, EcoCentric), Nubayr Zein (Egypt/UAE, Leaukeather), and Fella Bouti (Algeria, EcoTashira).

2024 LATAM Edition winners:
Valentina Agudelo (Colombia, Salva Health), Thamires Pontes (Brazil, Phycolabs), Leydi Cruz (Bolivia, Agrimet), Annie Rosas (Mexico, BlueKali), and Young Changemaker Kristal del Valle (Guatemala).

2025 South Asia Edition winners:
Nishat Palka (Bangladesh, MommyKidz), Amritha Krishnamoorthy (India, Stepping Stones Center), Jhillika Trisal (India, Cognitii), Nida Yousaf Sheikh (Pakistan, H20 Technologies), Sophiya Tamang (Nepal, Idea to Impact), and Yangchen Dorji (Bhutan, LEAD+).

Together they represent a global network of women redefining entrepreneurship – collaborating across sectors to drive innovation and shape a sustainable future.

Selection Process and Timeline

Semi-finalists will be selected by an independent Selection Committee composed of international business leaders and social impact experts. Finalists will be invited to participate in a regional bootcamp and pitch day, presenting their ventures to a distinguished jury of high-profile women leaders from the region.

The winners of the Unlock Her Future Prize 2026 East and Southeast Asia Edition will be announced in October 2026 during an awards ceremony at Shanghai Village, part of The Bicester Collection, which marks its 10th anniversary in 2026, underscoring the brand’s long-standing commitment to the region.

Applications are open until 30 April. For more information and to apply, visit: https://www.thebicestercollection.com/en/do-good/unlock-her-future-2026/

SYDNEY, March 16, 2026 /PRNewswire/ — Humanforce, a leading global provider of intelligent, AI-driven human capital management (HCM) solutions for frontline workforces, today announced the launch of Rewards & Recognition, new capabilities within Humanforce Benefits that use workforce data and event-triggered automation to recognise and reward frontline employees for everyday behaviours that drive operational performance.

Frontline industries, such as retail, healthcare, hospitality, childcare, aged care and logistics, face persistent challenges including high turnover, inconsistent compliance behaviours and disengagement in shift-based work environments. While the average employee turnover across Australian organisations sits at around 16 percent, frontline sectors like retail and hospitality often experience turnover rates exceeding 40 percent.

“Frontline organisations are under constant pressure to improve engagement, retention and compliance without increasing operational complexity,” said Clayton Pyne, CEO of Humanforce. “Recognition tied to everyday operational behaviours allows organisations to reinforce the actions that matter most. Too often, recognition programs sit outside the systems where frontline work actually happens. When actions such as attendance, task completion and teamwork are recognised in the moment, positive habits start to scale across the workforce.”

Unlike traditional recognition platforms designed for office-based employees and operating separately from workforce systems, Rewards & Recognition is embedded directly within the Humanforce platform and connected to workforce management and HR data, eliminating the need for additional tools or manual administration.

Built into the Humanforce Thrive employee app, Rewards & Recognition uses workforce data from across the Humanforce suite to automatically recognise every day operational behaviours in real time, including onboarding completion, on-time attendance and compliance tasks. Event-triggered automation allows organisations to reward these behaviours as they occur, without adding administrative burden for HR or operations teams. In addition, employees and managers can recognise great work through peer-to-peer recognition.

Employees can instantly redeem points for digital gift cards, while birthdays, work anniversaries and other key milestones are also recognised automatically within the platform.

“Traditional recognition programs usually sit outside the flow of daily work, which means they often fail in frontline environments,” Pyne said. “By connecting recognition directly to operational data and automating rewards based on workforce events, organisations can reinforce the behaviours that drive engagement, performance and compliance.”

Employee recognition is widely acknowledged as a powerful driver of engagement and retention. Gallup research shows employees who do not feel adequately recognised at work are twice as likely to leave their organisation within the next year.

“In fast-moving frontline environments, culture is built through the small daily moments, not annual reviews or a one-off instance,” Pyne added. “When recognition is tied to everyday operational behaviours, organisations can turn compliance into culture.”

Rewards & Recognition further expands Humanforce’s unified, AI-enabled HCM platform for frontline and flexible workforces, linking workforce data, automation and employee experience tools within the broader platform.

-ends-

About Humanforce

Humanforce provides the market leading, employee-centred, intelligent and compliant HCM suite for frontline and flexible workforces, offering highly configurable, all-in-one WFM, HR, Talent, Benefits and Payroll – without compromise. Our vision is to make work easier and life better by focusing on the employee experience (EX), and the efficiency and optimisation of businesses.

Founded in 2002, Humanforce has a 2300-strong customer base and is heading towards one million employees under management, across a wide range of industries including Aged Care, Childcare, Healthcare, Retail, Hospitality, Events & Stadia, Local Government and more. Today, we have offices across Australia, New Zealand, the United Kingdom, the Philippines, and the USA.

Customers include Accor, Flight Centre, Hungry Jack’s, Vodafone, Fujitsu, Alfred Health, Hostplus and more: https://humanforce.com

How agentic systems reshape marketing through continuous decision loops and synergies

SINGAPORE, March 16, 2026 /PRNewswire/ — Appier, an AI-native AaaS (Agentic AI as a Service) company, today announced the release of its latest whitepaper, “The Future of Autonomous Marketing with Agentic AI.” The report explores how agentic AI is emerging as a new operating layer for modern marketing organizations, shifting AI from reactive assistance toward autonomous planning, execution, and continuous optimization, further reinforcing Appier’s market position as a leader in the Agentic AI field.

From Automation to Autonomous Execution
Marketing is approaching a structural inflection point. This shift is not defined by incremental feature releases or model upgrades, but by a fundamental change in how AI systems operate within organizations.

As customer journeys become less linear and channel ecosystems grow more complex, marketing teams face a growing “Autonomy Gap”—the imbalance between manual human workflows and the sheer velocity of digital signals. Appier’s whitepaper demonstrates how agentic AI closes this gap by moving beyond simple “if-then” automation. Through continuous data iteration, closed-loop decision cycles, and coordinated execution frameworks, it effectively narrows this autonomy gap.

The report includes a deployment example in which activation timelines were reduced from three days to under one hour — representing up to a 24x improvement in operational velocity in those specific scenarios.

Beyond Large Language Models: The ‘Pilot’ Steering the AI Engine
The report clarifies the distinction between large language models (LLMs) and agentic AI architectures. While LLMs provide the core reasoning and content generation—acting as the powerful “engine” of the system—they lack the ability to independently execute complex goals or adapt behavior over time.

The evolution toward agentic AI introduces the “pilot” to this engine. By connecting reasoning with a coordinated system of action and learning, agentic AI transforms reactive LLMs into self-directing, adaptive marketing systems. This structural shift restores the “dignity of strategy” to marketers, liberating them from the burdens of manual orchestration and allowing them to focus on high-impact creative generation and strategic planning.

The Agentic Ecosystem: Elevating Strategy over Operations
The whitepaper suggests that the MarTech ecosystem is moving toward connected, autonomous systems that bridge the gap between insight and action. In this model, specialized agents across data intelligence, marketing activation, and conversational commerce work in a “closed-loop” growth engine, allowing real-time signals to move directly into coordinated execution across all touchpoints.

This evolution meaningfully changes how marketing teams allocate their expertise. As agentic systems autonomously handle high-volume operational tasks—such as audience discovery, multi-step test setups, and real-time campaign adjustments—marketers are liberated from manual orchestration. This transition allows teams to pivot toward higher-value responsibilities, including strategic oversight, creative storytelling, and cross-functional governance. In this environment, execution becomes less linear and more adaptive, functioning as a collaborative system aligned to measurable business outcomes.

A New Marketing Operating Model: Toward an Agentic Workforce
Appier views agentic AI not as a short-term trend, but as the foundation of a new marketing operating model. The core challenge for modern brands is no longer just access to data, but the ability to translate that insight into coordinated action at superhuman speed.

The future of marketing is not about adding more tools; it is about building a connected ‘Agentic Workforce’ where intelligence and execution exist in a continuous, self-improving loop. This transition enables organizations to move from reactive assistants to self-driving growth engines, ultimately delivering unprecedented business ROI and operational scale while allowing human talent to focus on high-impact creative decisions.

“The core challenge today is not simply access to data, but the ability to translate insight into coordinated action,” said Chih-Han Yu, CEO and Co-founder of Appier. “As marketing environments grow more complex, embedding autonomy into decision loops enables organizations to respond with greater agility while maintaining strategic oversight. This whitepaper outlines how agentic systems can help teams align execution more closely with business objectives.”

The full whitepaper, “The Future of Autonomous Marketing with Agentic AI,” which includes a strategic framework for evaluating agentic readiness, is available for download at Appier’s official website.

About Appier 
Appier (TSE: 4180) is an AI-native AaaS company that empowers businesses to create value through cutting edge AdTech and MarTech solutions. Founded in 2012 with the vision of “Making AI Easy,” Appier helps businesses turn Agentic AI into ROI through its Ad Cloud, Personalization Cloud, and Data Cloud—each powered by Agentic AI that enables autonomous, adaptive and real-time decision-making. Today, Appier operates 17 offices across APAC, the US and EMEA, and is listed on the Tokyo Stock Exchange. Learn more at www.appier.com.

– Targeting RE markets in Latin America and Asia-Pacific with product proven in Europe and OE sales

SEOUL, South Korea, March 15, 2026 /PRNewswire/ — NEXEN TYRE, a leading global tyre manufacturer, announced the launch of its high-performance summer tyre the N’BLUE S in Australia, as it accelerates its expansion in the global replacement (RE) market. Following its success in the European market, the company is now introducing this proven product to Australia to diversify its premium portfolio and support long-term growth in the Asia-Pacific region.

NEXEN TYRE’s launch of the N’BLUE S in Australia is part of the company’s premium global expansion strategy. Optimised for Australia’s diverse driving conditions, the N’BLUE S delivers exceptional stability on wet roads and superior efficiency in everyday driving. This launch marks a significant step forward in the company’s plan to diversify its regional portfolio and meet the structural demand for high-quality summer tyres in the Asia-Pacific region.

The N’BLUE S is a high-performance summer tyre designed with an optimised contact patch structure that reduces rolling resistance for better efficiency and improved handling. It is made from a multifunctional compound with evenly dispersed materials to enhance wet grip, ensuring stable driving on wet roads.

The newly launched N’BLUE S also carries NEXEN TYRE’s proprietary EV ROOT mark. This designation is granted to products engineered to deliver optimal performance across internal combustion engine, hybrid, and electric vehicles. As electrification accelerates globally, the company expects to broaden its sales base by offering a single product suitable for vehicles across diverse powertrains.

The N’BLUE S’s performance has already been proven in both the European replacement market and original equipment (OE) sales. It has been supplied as OE for European models as well as electric vehicles such as the Hyundai Casper EV, Kia Niro and PV5. NEXEN TYRE aims to build on the product’s proven competitiveness with global automakers by expanding consumer touchpoints through broader penetration into the replacement market.

NEXEN TYRE is strengthening its presence in Australia by enhancing both its logistics infrastructure and its retail competitiveness. With the opening of a new warehouse in Rocklea, Queensland in 2025, the company now operates three dedicated logistics hubs across New South Wales, Victoria, and Queensland. This has enabled significantly shorter lead times and superior inventory responsiveness for NEXEN TYRE’s partners nationwide. As part of its continued investment in the Australian market, the company is also planning to establish a new warehouse in Western Australia later this year further enhancing its nationwide distribution efficiency.

Starting in 2026, NEXEN TYRE AUSTRALIA plans to roll out its global retail branding program, the Nexen Point Dealer Program, nationwide. This will unify external signage, in-store interiors and merchandising guidelines to ensure a consistent brand experience. By integrating its three logistics hubs with a unified distribution and branding strategy, NEXEN TYRE aims to accelerate its growth in the local RE tyre market.

“The launch of the N’BLUE S in Australia reflects our commitment to delivering high-performance summer tyres across the Asia-Pacific region,” said John Bosco (Hyeon Suk) Kim, CEO of NEXEN TYRE. “With our strengthened local logistics and retail network, we will continue to expand our presence and enhance our competitive edge in the Australian replacement market.”

###

About NEXEN TYRE

Established in 1942, NEXEN TYRE is a global tyre manufacturer headquartered in South Korea. As one of the world’s fastest growing tyre manufacturers, the company does business in approximately 150 countries around the world and owns four manufacturing plants, two in Korea (Yangsan and Changnyeong), one in Qingdao, China, and a fourth in Žatec, Czech Republic, that began operation in 2019. NEXEN TYRE produces tyres for passenger cars, SUVs, and light trucks based on advanced technology and design excellence. As proof of their quality and technological excellence, the company’s OE tyres are used by global premium car makers in various countries around the world. In 2014, NEXEN TYRE achieved a grand slam by winning the world’s top four design awards, the first tyre maker in the world to do so.

For more information, please visit https://newsroom.nexentire.com/

– Targeting RE markets in Latin America and Asia-Pacific with product proven in Europe and OE sales

SEOUL, South Korea, March 15, 2026 /PRNewswire/ — NEXEN TYRE, a leading global tyre manufacturer, announced the launch of its high-performance summer tyre the N’BLUE S in Australia, as it accelerates its expansion in the global replacement (RE) market. Following its success in the European market, the company is now introducing this proven product to Australia to diversify its premium portfolio and support long-term growth in the Asia-Pacific region.

NEXEN TYRE’s launch of the N’BLUE S in Australia is part of the company’s premium global expansion strategy. Optimised for Australia’s diverse driving conditions, the N’BLUE S delivers exceptional stability on wet roads and superior efficiency in everyday driving. This launch marks a significant step forward in the company’s plan to diversify its regional portfolio and meet the structural demand for high-quality summer tyres in the Asia-Pacific region.

The N’BLUE S is a high-performance summer tyre designed with an optimised contact patch structure that reduces rolling resistance for better efficiency and improved handling. It is made from a multifunctional compound with evenly dispersed materials to enhance wet grip, ensuring stable driving on wet roads.

The newly launched N’BLUE S also carries NEXEN TYRE’s proprietary EV ROOT mark. This designation is granted to products engineered to deliver optimal performance across internal combustion engine, hybrid, and electric vehicles. As electrification accelerates globally, the company expects to broaden its sales base by offering a single product suitable for vehicles across diverse powertrains.

The N’BLUE S’s performance has already been proven in both the European replacement market and original equipment (OE) sales. It has been supplied as OE for European models as well as electric vehicles such as the Hyundai Casper EV, Kia Niro and PV5. NEXEN TYRE aims to build on the product’s proven competitiveness with global automakers by expanding consumer touchpoints through broader penetration into the replacement market.

NEXEN TYRE is strengthening its presence in Australia by enhancing both its logistics infrastructure and its retail competitiveness. With the opening of a new warehouse in Rocklea, Queensland in 2025, the company now operates three dedicated logistics hubs across New South Wales, Victoria, and Queensland. This has enabled significantly shorter lead times and superior inventory responsiveness for NEXEN TYRE’s partners nationwide. As part of its continued investment in the Australian market, the company is also planning to establish a new warehouse in Western Australia later this year further enhancing its nationwide distribution efficiency.

Starting in 2026, NEXEN TYRE AUSTRALIA plans to roll out its global retail branding program, the Nexen Point Dealer Program, nationwide. This will unify external signage, in-store interiors and merchandising guidelines to ensure a consistent brand experience. By integrating its three logistics hubs with a unified distribution and branding strategy, NEXEN TYRE aims to accelerate its growth in the local RE tyre market.

“The launch of the N’BLUE S in Australia reflects our commitment to delivering high-performance summer tyres across the Asia-Pacific region,” said John Bosco (Hyeon Suk) Kim, CEO of NEXEN TYRE. “With our strengthened local logistics and retail network, we will continue to expand our presence and enhance our competitive edge in the Australian replacement market.”

###

About NEXEN TYRE

Established in 1942, NEXEN TYRE is a global tyre manufacturer headquartered in South Korea. As one of the world’s fastest growing tyre manufacturers, the company does business in approximately 150 countries around the world and owns four manufacturing plants, two in Korea (Yangsan and Changnyeong), one in Qingdao, China, and a fourth in Žatec, Czech Republic, that began operation in 2019. NEXEN TYRE produces tyres for passenger cars, SUVs, and light trucks based on advanced technology and design excellence. As proof of their quality and technological excellence, the company’s OE tyres are used by global premium car makers in various countries around the world. In 2014, NEXEN TYRE achieved a grand slam by winning the world’s top four design awards, the first tyre maker in the world to do so.

For more information, please visit https://newsroom.nexentire.com/

MELBOURNE, Australia and INDIANAPOLIS, March 16, 2026 /PRNewswire/ — Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces the resubmission of a New Drug Application (NDA) to the United States (U.S.) Food and Drug Administration (FDA) for TLX101-Px, (Pixclara®^[1], Floretyrosine F 18 or ¹⁸F-FET), an investigational PET^[2] imaging agent for the characterization of recurrent or progressive glioma (brain cancer) from treatment related changes in both adult and pediatric patients.

Telix has resubmitted the NDA with the additional data requested by the FDA. The Company believes, based on the Type A meeting and ongoing consultation with the FDA, that the additional data and statistical analysis, along with the primary data set provided in the original submission, appropriately addresses the Complete Response Letter^[3].

Given the potential to address significant unmet medical need, TLX101-Px has been granted Orphan Drug^[4] and Fast Track^[5] designations by the FDA. PET imaging with ¹⁸F-FET is already included in international clinical practice guidelines for the imaging of gliomas^[6], however there is currently no FDA-approved targeted amino acid PET agent for adult and pediatric brain cancer imaging commercially available in the U.S.

Dr. David N. Cade, Telix Group Chief Medical Officer, said, “We appreciate the FDA’s recognition of the critical unmet need to improve the diagnosis and management of glioma, particularly in the post-treatment setting. Our resubmission is supported by an extensive and compelling data set – particularly so for an orphan indication. We are grateful to our global clinical collaborators, who share our commitment to ensuring patients in the U.S. can benefit from this important patient management tool.”

Maggie Haynes, Executive Director, Head for the Cure Foundation, added: “Our community is encouraged by the FDA’s ongoing engagement and guidance to the sponsor and support for the Expanded Access Program for TLX101-Px. We are hopeful of an expedited review, so this important and proven imaging option can become available to those who urgently need it.”

About TLX101-Px

TLX101-Px is a PET imaging agent, which has been granted fast track and orphan drug designations by the FDA as an imaging agent for the characterization of recurrent or progressive glioma from treatment related changes. TLX101-Px targets membrane transport proteins known as LAT1 and LAT2^[7]. This enables TLX101-Px to be potentially utilized as a companion diagnostic agent to TLX101-Tx (iodofalan ¹³¹I), Telix’s LAT1-targeting glioblastoma (GBM) therapy candidate, currently under investigation in the pivotal IPAX-BrIGHT study^[8]. 

About gliomas in the U.S.

Gliomas are very diffusely infiltrative tumors that affect the surrounding brain tissue. They are the most common form of central nervous system (CNS) neoplasm that originates from glial cells, accounting for approximately 30% of all brain and CNS tumors and 80% of all malignant brain tumors^[9]. In the U.S., there are six cases of gliomas diagnosed per 100,000 people every year^[10]. GBM is a high-grade glioma and the most common and aggressive form of primary brain cancer, with approximately 22,000 new cases diagnosed annually in the U.S.^[11]. The mainstay of treatment for GBM comprises surgical resection, followed by combined radiotherapy and chemotherapy. Despite such treatment, recurrence occurs in almost all patients^[12], with an expected survival duration of 12-15 months from diagnosis^[13]. 

About Telix Pharmaceuticals Limited

Telix is a global biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies, with the goal to address significant unmet medical needs in oncology and rare diseases. With international operations in the United States, United Kingdom, Brazil, Canada, Europe (Belgium and Switzerland), and Japan, Telix is headquartered in Melbourne, Australia. Telix is listed on the Australian Securities Exchange (ASX: TLX) and the Nasdaq Global Select Market (NASDAQ: TLX).

Illuccix® (kit for the preparation of gallium-68 (⁶⁸Ga) gozetotide injection), Telix’s first generation PSMA-PET imaging agent, has been approved in multiple markets globally. Gozellix® (kit for the preparation of gallium-68 (⁶⁸Ga) gozetotide injection) has been approved by the U.S. FDA^[14]. TLX101-Px and TLX101-Tx have not received marketing authorizations in any jurisdiction.

Visit www.telixpharma.com for further information about Telix, including details of the latest share price, ASX and U.S. Securities and Exchange Commission (SEC) filings, investor and analyst presentations, news releases, event details and other publications that may be of interest. You can also follow Telix on LinkedIn, X and Facebook.

This announcement has been authorized for release by the Telix Pharmaceuticals Limited Disclosure Committee on behalf of the Board.

Legal Notices

Cautionary Statement Regarding Forward-Looking Statements. 

You should read this announcement together with our risk factors, as disclosed in our most recently filed reports with the Australian Securities Exchange (ASX), U.S. Securities and Exchange Commission (SEC), including our Annual Report on Form 20-F filed with the SEC, or on our website.

The information contained in this announcement is not intended to be an offer for subscription, invitation or recommendation with respect to securities of Telix Pharmaceuticals Limited (Telix) in any jurisdiction, including the United States. The information and opinions contained in this announcement are subject to change without notification.  To the maximum extent permitted by law, Telix disclaims any obligation or undertaking to update or revise any information or opinions contained in this announcement, including any forward-looking statements (as referred to below), whether as a result of new information, future developments, a change in expectations or assumptions, or otherwise. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained or opinions expressed in the course of this announcement.

This announcement may contain forward-looking statements, including within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as “may”, “expect”, “intend”, “plan”, “estimate”, “anticipate”, “believe”, “outlook”, “forecast” and “guidance”, or the negative of these words or other similar terms or expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on Telix’s good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect Telix’s business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix’s business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress, completion and results of Telix’s preclinical and clinical trials, and Telix’s research and development programs; Telix’s ability to advance product candidates into, enroll and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals for Telix’s product candidates, including the planned NDA resubmission for TLX101-Px and the planned BLA resubmission for TLX250-Px, manufacturing activities and product marketing activities; Telix’s sales, marketing and distribution and manufacturing capabilities and strategies; the commercialization of Telix’s product candidates, if or when they have been approved; Telix’s ability to obtain an adequate supply of raw materials at reasonable costs for its products and product candidates; estimates of Telix’s expenses, future revenues and capital requirements; Telix’s financial performance; developments relating to Telix’s competitors and industry; the anticipated impact of U.S. and foreign tariffs and other macroeconomic conditions on Telix’s business; and the pricing and reimbursement of Telix’s product candidates, if and after they have been approved. Telix’s actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements.

Trademarks and Trade Names. All trademarks and trade names referenced in this press release are the property of Telix Pharmaceuticals Limited (Telix) or, where applicable, the property of their respective owners. For convenience, trademarks and trade names may appear without the ® or ™ symbols. Such omissions are not intended to indicate any waiver of rights by Telix or the respective owners. Trademark registration status may vary from country to country. Telix does not intend the use or display of any third-party trademarks or trade names to imply any affiliation with, endorsement by, or sponsorship from those third parties.

©2026 Telix Pharmaceuticals Limited. All rights reserved.